Jane Street’s CytomX Therapeutics CTMX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$204K Sell
43,400
-46,400
-52% -$236K ﹤0.01% 10108
2025
Q4
$383K Buy
89,800
+48,600
+118% +$185K ﹤0.01% 8294
2025
Q3
$131K Sell
41,200
-21,400
-34% -$48.2K ﹤0.01% 9969
2025
Q2
$142K Buy
+62,600
New +$101K ﹤0.01% 8789
2024
Q2
Sell
-37,100
Closed -$80.9K 9477
2024
Q1
$80.9K Buy
+37,100
New +$68.5K ﹤0.01% 8607

Other funds holding CTMX

Jane Street's CTMX Position: Q1 2026 in Review

Jane Street increased its CytomX Therapeutics (CTMX) stake by 64% in Q1 2026, buying an estimated $1.98M and bringing the position to 997,510 shares worth $4.69M. The position accounts for ﹤0.01% of the portfolio, ranked #3621.

Jane Street first reported a position in CTMX in Q2 2020 and has held it in 20 quarters since. 179 funds tracked by Wall St. Rank hold CTMX as of Q1 2026.

  • Jane Street held 997,510 shares of CytomX Therapeutics worth $4.69M as of Q1 2026.
  • Jane Street bought 390,292 CytomX Therapeutics shares in Q1 2026, an estimated $1.98M.
  • CytomX Therapeutics made up ﹤0.01% of Jane Street's portfolio in Q1 2026, its #3621 holding.
  • Jane Street first reported a position in CytomX Therapeutics in Q2 2020 and has held it in 20 quarters since.
  • 179 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q1 2026.

Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.